Additionally, analysis of proteomics data from the Clinical Proteomic Tumour Analysis Consortium (CPTAC) confirmed that SOX9 protein expression in glioma tissue is significantly higher than that in normal brain tissue, and this pattern is consistent with the changes observed for USP18 expression (Fig. S4B). This evidence concerns the gene SOX9 and central nervous system cancer.